参考文献/References:
[1] 张荒生,陈丽川,王进军,等.痹痛定分散片对大鼠AA模型血清TGF-β1及滑膜组织病理形态学的影响[J].光明中医,2009,24(4):648-651.
[2] 王婷,张金超.抗骨质疏松症的单味中药及药用植物研究进展[J].中国中药杂志,2006,31(5):719-722.
[3] 陈顺,关延彬.骨碎补药理作用的研究进展[J].医药导报,2006,25(7):685.
[4] 昝强,朱超,屈强,等.强骨汤治疗肾虚型骨质疏松症56例[J].陕西中医,2006,27(8):957-959.
[5] 黄永明,许少健,石宇雄,等.骨松安胶囊治疗绝经后骨质疏松症34例[J].陕西中医,2006,27(8):954-956.
[6] 周军杰,曹成福,纪斌,等.丹黄补骨方调控骨形成功能的疗效特征[J].中国临床康复,2006,10(31):37-40.
[7] 柳景红.抗骨衰丸对原发性骨质疏松症患者临床证候及相关实验室指标的干预[J].中国临床康复,2006,10(23):13-17.
[8] 王和鸣,葛继荣,田金洲,等.强骨胶囊治疗原发性骨质疏松症临床试验[J].中药新药与临床药理,2004,15(4):284-287.
[9] 张勇军.骨碎补总黄酮对去卵巢大鼠OPG和血清TRACP表达的影响[J].中南大学,2009,10(1):13-18.
[10] Mandelin J,Li TF,LiljeströmM,et al.Imbalance of RANKL/RANK/OPG system in interface tissue in loosening of total hip replacement[J].J Bone Joint Surg Br, 2003,85(8):1196-1201.
[11] Adachi JD,Saag KG,DelmasPD,et al.Two-year effects of alen-dronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids:a randomized,double-blind,placebo-controlled extension trial[J].Arthritis Rheum 2001,44(1):202-211.
[12] Hofbauer LC,Heufelder AE.The role of receptor activator of nuclear factor-kappa B ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases[J].J Clin Endocrinol Metab,2000,85(7):2355-2363.
[13] Burgess TL,Qian Y,Kaufman S,et al.The ligand for osteoprotegerin(OPGL)directly activates mature osteoclasts[J].J Cell Biol,1999,145(3):527-538.
[14] Wei S,Wang MW,Teitelbaum SL,et al.Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-kappa B and mitogen-activated protein kinase signaling[J].J Biol Chem,2002,277(8):6622-6630.
[15] Karsdal MA,Hjorth P,Henrisken K,et al.Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression[J].J Biol Chem,2003,278(45):44975-44987.
[16] Kostenuik PJ,Bolon B,Morony S,et al.Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice[J].Bone,2004,34(4):656-664.
[17] Hofbauer LC,Khosla S,Dunstan CR,et al.The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption[J].J Bone Miner Res,2000,15(1):2-12.
[18] Bekker PJ,Holloway D,Nakanishi A,et al.The effect of a single dose of osteoproteger in postmenopausal women[J].J Bone Miner Res,2001,16(2):348-360.
[19] 廖悦华,梁琼,王卓,等.中药骨碎补对去睾丸骨质疏松症动物模型的影响[J].中国骨质疏松杂志,2007,13(4):277-280.
[20] 谢雁鸣,赵晋宁,丁会,等.强骨胶囊抗去势大鼠骨质疏松症的实验研究[J].中国中医药科技,2000,7(3):151-152.
[21] 黄秀兰,周亚伟,王伟.淫羊藿黄酮类化合物药理研究进展[J].中成药,2005,27(6):719-721.
[22] 宋丽华,肖洲生,周宏灏.植物性雌激素的研究进展[J].国外医学:药学分册,2003,30(1):25-29.
[23] Nifli AP,Bosson-Kouamé A,Papadopoulou N,et al.Monomeric and oligomeric flavanols are agonists of membrane and rogen receptors[J].Exp Cell Res,2005,309(2):329-339.